Bitterroot Bio and Biotheus announce research collaboration to develop bispecific proteins in cardio-immunology.

Pictured: Map of NextGen Class of 2024/BioSpaceBioSpace is proud to present its NextGen Bio Class of 2024, a list of the hottest new life sciences companies in the United States. To come up with this list, BioSpace identified companies that launched between September 2022 and September 2023 with Series A funding. They were then assessed using several different criteria including finance, partnerships, pipeline, growth potential and innovation. After awarding points for each category, the BioSpace editorial team ranked its top 30. The impressive group of startups that make up BioSpace’s NextGen Class of 2024 is already making an impact on the industry. We will continue to keep a close eye on these companies as we move into the new year. Launched: March 2023Location: Boston, MA, and San Diego, CASeries A: $100MSeries B: $150MNotable: Good rapport won this startup top billing on our list. The product of a partnership between Third Rock Ventures and Janssen Neuroscience, Rapport’s first program focuses on targeting drug-resistant seizure disorders and is in Phase I development.Differentiator: Specificity is what sets Rapport apart, according to CEO Abe Ceesay, who spoke with BioSpace in March 2023

Bitterroot Bio, a Palo Alto-based developer of immunotherapies for cardiovascular disease, raised $145 million in Series A funding co-led by Arch Venture Partners and Deerfield Management.